These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 8102552

  • 21. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.
    Glazer WM, Morgenstern H, Schooler N, Berkman CS, Moore DC.
    Br J Psychiatry; 1990 Oct; 157():585-92. PubMed ID: 1983390
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. A 10-year follow-up study of tardive dyskinesia.
    Yassa R, Nair NP.
    Acta Psychiatr Scand; 1992 Oct; 86(4):262-6. PubMed ID: 1360742
    [Abstract] [Full Text] [Related]

  • 27. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study.
    Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V.
    J Clin Psychiatry; 2007 Jul; 68(7):1031-7. PubMed ID: 17685739
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine.
    Bodkin JA, Cohen BM, Salomon MS, Cannon SE, Zornberg GL, Cole JO.
    J Nerv Ment Dis; 1996 May; 184(5):295-301. PubMed ID: 8627275
    [Abstract] [Full Text] [Related]

  • 30. Naltrexone treatment of tardive dyskinesia in patients with schizophrenia.
    Wonodi I, Adami H, Sherr J, Avila M, Hong LE, Thaker GK.
    J Clin Psychopharmacol; 2004 Aug; 24(4):441-5. PubMed ID: 15232337
    [Abstract] [Full Text] [Related]

  • 31. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
    Kopala LC, Honer WG.
    J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A trial of L-deprenyl for the treatment of neuroleptic-induced parkinsonism.
    Rapoport A, Stein D, Schwartz M, Levin J, Stier S, Elizur A, Rabey JM.
    J Neural Transm (Vienna); 1999 Dec; 106(9-10):911-8. PubMed ID: 10599872
    [Abstract] [Full Text] [Related]

  • 35. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia.
    Suddath RL, Straw GM, Freed WJ, Bigelow LB, Kirch DG, Wyatt RJ.
    Pharmacol Biochem Behav; 1991 Jul; 39(3):743-5. PubMed ID: 1686106
    [Abstract] [Full Text] [Related]

  • 36. Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
    Rajarethinam R, Dziuba J, Manji S, Pizzuti A, Lachover L, Keshavan M.
    World J Biol Psychiatry; 2009 Jul; 10(4 Pt 2):416-9. PubMed ID: 19492247
    [Abstract] [Full Text] [Related]

  • 37. Progress in the treatment of tardive dyskinesia: theory and practice.
    Feltner DE, Hertzman M.
    Hosp Community Psychiatry; 1993 Jan; 44(1):25-34. PubMed ID: 8094705
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Deprenyl augmentation for treating negative symptoms of schizophrenia: a double-blind, controlled study.
    Jungerman T, Rabinowitz D, Klein E.
    J Clin Psychopharmacol; 1999 Dec; 19(6):522-5. PubMed ID: 10587287
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.